The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Items 601–700 of 1,004
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
Gremke, N., Besong, I., Stroh, A., von Wichert, L., Witt, M., Elmshäuser, S., Wanzel, M., Fromm, M. F., Taudte, R. V., Schmatloch, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02180-4 · Cited by 31
Self-citationAdvancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications
Qiu, P., Yu, X., Zheng, F., Gu, X., Huang, Q., Qin, K., Hu, Y., Liu, B., Xu, T., Zhang, T., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102979 · Cited by 34
Molecular Classification of Gastric Cancer among Alaska Native People
Martinson, H. A., Mallari, D., Richter, C. E., Wu, T., Tiesinga, J. J., Alberts, S., & Olnes, M. J. (2020) · Cancers · doi:10.3390/cancers12010198 · Cited by 27
Fang, B., Kannan, A., Zhao, S., Nguyen, Q., Ejadi, S., Yamamoto, M., Barreto, J. C., Zhao, H., & Gao, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65637-2 · Cited by 29
Lu, Y., Lee, K. S., Chao, T.-Y., Tseng, L., Chitapanarux, I., Chen, S., Liu, C.-T., Sohn, J., Kim, J. H., Chang, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1008 · Cited by 27
Self-citationMcPhail, J. A., & Burke, J. E. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_9 · Cited by 26
Sultova, E., Westphalen, C. B., Jung, A., Kumbrink, J., Kirchner, T., Mayr, D. C., Rudelius, M., Ormanns, S., Heinemann, V., Metzeler, K. H., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11040733 · Cited by 27
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey, N., Aske, J. C., & Pradip, D. (2021) · Pharmaceuticals · doi:10.3390/ph14050455 · Cited by 26
Holzhauser, S., Wild, N., Zupancic, M., Ursu, R. G., Bersani, C., Näsman, A., Kostopoulou, O. N., & Dalianis, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640490 · Cited by 27
Lin, D. I., Fine, A. D., Danziger, N. A., Huang, R. S. P., Mata, D. A., Decker, B. J., Killian, J. K., Ramkissoon, S. H., Lechpammer, M., Janovitz, T., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.12.030 · Cited by 27
Racial Differences in Genomic Profiles of Breast Cancer
Goel, N., Kim, D. Y., Guo, J. A., Zhao, D. Y., Mahal, B. A. V., & Alshalalfa, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0573 · Cited by 27
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
Lai, H.-Z., Han, J., Fu, X., Ren, Y., Li, Z., & You, F.-M. (2022) · Cancers · doi:10.3390/cancers14153774 · Cited by 27
PIK3CA is recurrently mutated in canine mammary tumors, similarly to in human mammary neoplasia
Arendt, M. L., Sakthikumar, S., Melin, M., Elvers, I., Rivera, P., Larsen, M., Saellström, S., Lingaas, F., Rönnberg, H., & Lindblad‐Toh, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-27664-7 · Cited by 27
Daher, S., Zer, A., Tschernichovsky, R., Yacobi, R., Barshack, I., Tsabari, S., Rottenberg, Y., Zick, A., Gottfried, T., Lobachov, A., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.02.023 · Cited by 28
New Biomarkers and Treatment Advances in Triple-Negative Breast Cancer
Hejjioui, B. E., Lamrabet, S., Joutei, S. A., Senhaji, N., Bouhafa, T., Malhouf, M. A., Bennis, S., & Bouguenouch, L. (2023) · Diagnostics · doi:10.3390/diagnostics13111949 · Cited by 28
Tang, J., Liu, J., He, X., Fu, S., Wang, K., Li, C., Li, Y., Zhu, Y., Gong, P., Zhao, Y., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00287 · Cited by 26
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
Ketcham, J. M., Harwood, S. J., Aranda, R., Aloiau, A. N., Bobek, B. M., Briere, D. M., Burns, A. C., Haatveit, K. C., Calinisan, A., Clarine, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00078 · Cited by 26
Signaling pathway dysregulation in breast cancer
Ryspayeva, D., Seyhan, A. A., MacDonald, W., Purcell, C., Roady, T. J., Ghandali, M., Verovkina, N., El‐Deiry, W. S., Taylor, M. S., & Graff, S. L. (2025) · Oncotarget · doi:10.18632/oncotarget.28701 · Cited by 31
Baird, R. D., van Rossum, A. G. J., Oliveira, M., Beelen, K. J., Gao, M., Schrier, M., Mandjes, I. A. M., García-Corbacho, J., Vallier, A.-L., Dougall, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0508 · Cited by 28
Evolution of Molecular Targets in Melanoma Treatment
Tran, K. B., Buchanan, C. M., & Shepherd, P. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200130091318 · Cited by 26
Schwartzberg, L. S., & Vidal, G. A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.02.002 · Cited by 27
Genomic Alteration in Metastatic Breast Cancer and Its Treatment
Li, A., Schleicher, S. M., André, F., & Mitri, Z. I. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280463 · Cited by 26
Self-citationLin, D. I., Killian, J. K., Venstrom, J. M., Ramkissoon, S. H., Ross, J. S., & Elvin, J. A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00699-1 · Cited by 27
Ribelles, N., Jerez, J. M., Rodríguez-Brazzarola, P., Jiménez, B., Díaz-Redondo, T., Mesa, H., Márquez, A., Sánchez‐Muñoz, A., Pajares, B., Carabantes, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.030 · Cited by 26
Somatic non-cancerous PIK3CA-related overgrowth syndrome treated with alpelisib in North America
Garneau, A. P., Haydock, L., Tremblay, L., & Isenring, P. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-020-02030-6 · Cited by 26
Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules
Elkaeed, E. B., Salam, H. A. A. E., Sabt, A., Al-Ansary, G. H., & Eldehna, W. M. (2021) · Molecules · doi:10.3390/molecules26247611 · Cited by 27
Tung, H., Wu, R., Lin, C., & Lai, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073794 · Cited by 26
Cho, Y. A., Ko, S. Y., Suh, Y. J., Kim, S., Park, J. H., Park, H., Seo, J., Choi, H. G., Kang, H. S., Lim, H. S., et al. (2022) · Current Oncology · doi:10.3390/curroncol29050236 · Cited by 26
Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations
Chen, J. W., Murugesan, K., Newberg, J. Y., Sokol, E. S., Savage, H. M., Stout, T. J., Maund, S. L., & Hutchinson, K. E. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00341 · Cited by 26
Discovery and biosynthesis of karnamicins as angiotensin converting enzyme inhibitors
Yu, Z., Huang, J., Yang, J., Liu, C., Yan, Y., Wang, L., Zhao, J., Chen, Y., Xiang, W., & Huang, S. (2023) · Nature Communications · doi:10.1038/s41467-023-35829-1 · Cited by 26
Mansur, A., & Radovanovic, I. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1099328 · Cited by 26
The role of TSC2 in breast cancer: a literature review
Zhu, Q., He, Z.-M., Cao, W., & Li, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1188371 · Cited by 26
Rosin, J., Svegrup, E., Valachis, A., & Zerdes, I. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07010-1 · Cited by 28
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
Bhin, J., Yemelyanenko, J., Chao, X., Klarenbeek, S., Opdam, M., Malka, Y., Hoekman, L., Kruger, D. T., Bleijerveld, O. B., Brambillasca, C. S., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20211743 · Cited by 28
Montagna, E., & Colleoni, M. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919894105 · Cited by 28
Alpelisib for PIK3CA -Mutated Advanced Breast Cancer
André, F., Mills, D., & Taran, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1907856 · Cited by 26
Self-citationYuan, J., Li, Y., Li, Z., Zhang, H., Wang, Q., Huang, J., Wang, B., Mohan, C. D., Sethi, G., & Wang, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1261283 · Cited by 26
Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., Nishio, K., et al. (2024) · Cancers · doi:10.3390/cancers16061184 · Cited by 28
Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies
Romaniuk-Drapała, A., Totoń, E., Taube, M., Idzik, M., Rubiś, B., & Lisiak, N. (2024) · Cancers · doi:10.3390/cancers16132481 · Cited by 27
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities
Rosenberger, L. H., Riedel, R. F., Diego, E. J. B., Nash, A. L., Grilley‐Olson, J. E., Danziger, N. A., Sokol, E. S., Ross, J. S., & Sammons, S. L. (2024) · The Oncologist · doi:10.1093/oncolo/oyae218 · Cited by 25
Fanucci, K. A., Giordano, A., Erick, T. K., Tolaney, S. M., & Sammons, S. L. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103997 · Cited by 26
Askeland, C., Wik, E., Finne, K., Birkeland, E., Arnes, J. B., Collett, K., Knutsvik, G., Krüger, K., Davidsen, B., Aas, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59728-3 · Cited by 24
Freitag, C. E., Mei, P., Wei, L., Parwani, A. V., & Li, Z. (2020) · Human Pathology · doi:10.1016/j.humpath.2020.05.005 · Cited by 25
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 29
Self-citationHui, R., BOER, R. D., Lim, E., Yeo, B. J., & Lynch, J. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13555 · Cited by 25
Manca, P., Corallo, S., Busico, A., Lonardi, S., Corti, F., Antoniotti, C., Procaccio, L., Clavarezza, M., Smiroldo, V., Tomasello, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4699 · Cited by 25
Mantilla, W. A., Sanabria‐Salas, M. C., Baldión, A. M., Sua, L. F., Gonzalez, D. M., & Lema, M. (2021) · JCO Global Oncology · doi:10.1200/go.21.00046 · Cited by 25
Cirmena, G., Dameri, M., Ravera, F., Fregatti, P., Ballestrero, A., & Zoppoli, G. M. (2021) · Cancers · doi:10.3390/cancers13143460 · Cited by 29
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
García‐Foncillas, J., Argente, J., Bujanda, L., Cardona, V., Casanova, B., Montés, A. F., Horcajadas, J. A., Íñiguez, A., Ortíz, A., Pablos, J. L., et al. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00544-4 · Cited by 27
Wooster, M. E., McGuinness, J. E., Fenn, K. M., Singh, V., Franks, L. E., Lee, S. Y., Cieremans, D. A., Lassman, A. B., Hershman, D. L., Crew, K. D., et al. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.11.002 · Cited by 25
New Advances in Targeted Therapy of HER2-Negative Breast Cancer
An, J., Peng, C. Y., Xie, X., & Peng, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.828438 · Cited by 26
Catalytic Asymmetric Construction of CF3-Substituted Chiral sp3 Carbon Centers
Hirano, K. (2022) · Synthesis · doi:10.1055/a-1833-8813 · Cited by 24
Kumarasamy, V. M., Nambiar, R., Wang, J., Rosenheck, H. R., Witkiewicz, A. K., & Knudsen, E. S. (2022) · Oncogene · doi:10.1038/s41388-022-02362-2 · Cited by 25
Venetis, K., Pepe, F., Munzone, E., Sajjadi, E., Russo, G., Pisapia, P., Ivanova, M. D., Bonizzi, G., Vacirca, D., Rappa, A., et al. (2022) · Cells · doi:10.3390/cells11223545 · Cited by 26
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors
Wei, X., Liu, F., Liu, J., Zhao, H., Zhang, Y., Wang, Z., Qiu, M., Xu, F., Yu, Q.-Q., Du, Y.-W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34782-9 · Cited by 25
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 25
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Ashai, N., & Swain, S. M. (2023) · Cancers · doi:10.3390/cancers15061855 · Cited by 25
The Challenges of Treating Patients with Breast Cancer and Obesity
LeVee, A. A., & Mortimer, J. E. (2023) · Cancers · doi:10.3390/cancers15092526 · Cited by 27
Chiu, J. W. Y., Su, F., Joshi, M., Masuda, N., Ishikawa, T., Aruga, T., Zarate, J. P., Babbar, N., Balbin, O. A., & Yap, Y. S. (2023) · BMC Medicine · doi:10.1186/s12916-023-03017-z · Cited by 27
Breast cancer and its therapeutic targets: A comprehensive review
Singh, A., Mishra, R., & Mazumder, A. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14384 · Cited by 25
The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2023) · Cancers · doi:10.3390/cancers15225463 · Cited by 25
Shen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 26
Breast Cancer: 45 Years of Research and Progress
Hortobágyi, G. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00199 · Cited by 27
Llombart‐Cussac, A., Harper-Wynne, C. L., Perelló, A., Hennequin, A., Fernández-Ortega, A., Colleoni, M. A., Marín, S., Quiroga, V., Médioni, J., Iranzo, V., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01865 · Cited by 29
Giugliano, F., Angelis, C. D., Pistilli, B., Viale, G., Bianchini, G., Giuliano, M., Malorni, L., Salimbeni, B. T., Espósito, A., Giordano, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102980 · Cited by 26
de Abreu, A. R., Wyninckx, A., Vandamme, T., de Beeck, K. O., Camp, G. V., Peeters, M., Laurent‐Puig, P., Taı̈eb, J., Taly, V., & Benhaïm, L. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf204 · Cited by 29
Jacot, W., Dalenc, F., Lopez‐Crapez, E., Chaltiel, L., Durigova, A., Gros, N., Lozano, N., Lacaze, J., Pouderoux, S., Gladieff, L., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05349-y · Cited by 24
Blomquist, M. R., Ensign, S. P. F., D’Angelo, F., Phillips, J. J., Ceccarelli, M., Peng, S., Halperin, R. F., Caruso, F. P., Garofano, L., Byron, S. A., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa078 · Cited by 24
Berquez, M., Gadsby, J. R., Festa, B. P., Butler, R., Jackson, S. P., Berno, V., Luciani, A., Devuyst, O., & Gallop, J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.05.040 · Cited by 24
Gajewska, M., Blumenstein, L., Kourentas, A., Mueller‐Zsigmondy, M., Lorenzo, S., Sinn, A., Velinova, M. J., & Heimbach, T. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00511-7 · Cited by 24
Holzhauser, S., Lukoseviciute, M., Papachristofi, C., Vasilopoulou, C., Herold, N., Wickström, M., Kostopoulou, O. N., & Dalianis, T. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5167 · Cited by 24
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Lerebours, F., Cabel, L., & Pierga, J. (2021) · Cancers · doi:10.3390/cancers13040902 · Cited by 26
Leung, J. H., Leung, H. W. C., Wang, S.-Y., Huang, S.-S., & Chan, A. L. F. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1931116 · Cited by 23
Blow, T., Hyde, P. N., Falcone, J. N., Neinstein, A. B., Vasan, N., Chitkara, R., Hurd, M. A., Sardesai, S. D., Lustberg, M. B., Flory, J., et al. (2021) · Integrative Cancer Therapies · doi:10.1177/15347354211032283 · Cited by 23
Banys-Paluchowski, M. J., Fehm, T. N., Grimm, D., Rody, A., & Krawczyk, N. (2021) · Oncology Research and Treatment · doi:10.1159/000520561 · Cited by 24
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
Dai, M., Chen, S., Teng, X., Chen, K., & Cheng, W. (2022) · Journal of Cancer · doi:10.7150/jca.76695 · Cited by 28
Ye, Y., Huang, Z., Zhang, M., Li, J., Zhang, Y., & Lou, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114183 · Cited by 27
How I treat endocrine-dependent metastatic breast cancer
Gombos, A., Gonçalvès, A., Curigliano, G., Bartsch, R., Kyte, J., Ignatiadis, M., & Awada, A. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100882 · Cited by 25
Tharin, Z., Richard, C., Dérangère, V., Ilie, A., Arnould, L., Ghiringhelli, F., Boidot, R., & Ladoire, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-31593-w · Cited by 24
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
García-Sáenz, J. Á., Blancas, I., Echavarría, I., Hinojo, C., Vila, M. M., Moreno, F., Pernas, S., y Cajal, T. R., Ribelles, N., & Bellet, M. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03203-8 · Cited by 26
Miyashita, M., Bell, J. S. K., Wenric, S., Karaesmen, E., Rhead, B., Kase, M., Kaneva, K., Vega, F. M. D. L., Zheng, Y., Yoshimatsu, T. F., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01627-2 · Cited by 25
Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 27
MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer
Alday-Parejo, B., Richard, F., Wörthmüller, J., Rau, T. T., Galván, J. A., Desmedt, C., Santamaria‐Martínez, A., & Rüegg, C. (2020) · Cancers · doi:10.3390/cancers12010223 · Cited by 23
Llombart‐Cussac, A., Pérez-García, J. M., Borrego, M. R., Tolosa, P., Blanch, S., Fernández-Ortega, A., Urruticoechea, A., Blancas, I., Saura, C., Rojas, B., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102520 · Cited by 27
Self-citationThe PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer
Mallick, S., Duttaroy, A. K., & Dutta, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102140 · Cited by 23
mTOR inhibitors as potential therapeutics for endometriosis: a narrative review
Nakamura, A., Tanaka, Y., Amano, T., Takebayashi, A., Takahashi, A., Hanada, T., Tsuji, S., & Murakami, T. (2024) · Molecular Human Reproduction · doi:10.1093/molehr/gaae041 · Cited by 24
Mao, N., Lee, Y. S., Salsabeel, N., Zhang, Z., Li, D., Kaur, H., Chen, X., Chang, Q., Mehta, S., Barnes, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq3802 · Cited by 24
Wang, M., Li, J., Huang, J., & Luo, M. (2020) · BioMed Research International · doi:10.1155/2020/1598037 · Cited by 23
Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age
Holowatyj, A. N., Eng, C., Wen, W., Idrees, K., & Guo, X. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.28644 · Cited by 23
Franzoi, M. A., Saúde-Conde, R., Cristóvão‐Ferreira, S., Eiger, D., Awada, A. H., & de Azambuja, E. (2021) · The Breast · doi:10.1016/j.breast.2021.03.002 · Cited by 23
Paoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1562 · Cited by 23
Al-Qasem, A. J., Alves, C. L., & Ditzel, H. J. (2021) · Cancers · doi:10.3390/cancers13215397 · Cited by 25
Brito, C., Tomás, A., Azevedo, A., Esteves, S., Mafra, M., Roque, L., & Pojo, M. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211068804 · Cited by 23
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 25
Bontoux, C., Simonin, M., Garnier, N., Lhermitte, L., Touzart, A., Andrieu, G. P., Bruneau, J., Lengliné, É., Pleșa, A., Boissel, N., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01085-9 · Cited by 23
Ye, W., Lin, S., Zhi, W., Chu, T., Liu, B., Peng, T., Xu, M., Ding, W., Cao, C., & Wu, P. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28656 · Cited by 23
Hutchinson, K. E., Chen, J. W., Savage, H. M., Stout, T. J., Schimmöller, F., Cortés, J., Dent, S. F., Harbeck, N., Jacot, W., Krop, I. E., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01181-8 · Cited by 23
Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 24
Personalized treatment approach for HER2-positive metastatic breast cancer
Pandey, P., Chaudhary, R., Tripathi, D., Lavudi, K., Dua, K., Weinfeld, M., Lavasanifar, A., & Rajinikanth, P. S. (2024) · Medical Oncology · doi:10.1007/s12032-024-02504-4 · Cited by 26
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
